Biomedical imaging,especially molecular imaging,has been a driving force in scientific discovery,technological innovation,and precision medicine in the past two decades.While substantial advances and discoveries in ch...Biomedical imaging,especially molecular imaging,has been a driving force in scientific discovery,technological innovation,and precision medicine in the past two decades.While substantial advances and discoveries in chemical biology have been made to develop molecular imaging probes and tracers,translating these exogenous agents to clinical application in precision medicine is a major challenge.Among the clinically accepted imaging modalities,magnetic resonance imaging(MRI)and magnetic resonance spectroscopy(MRS)exemplify the most effective and robust biomedical imaging tools.Both MRI and MRS enable a broad range of chemical,biological diagnosis and characterization of many diseases and image-guided interventions.Using chemical,biological,and nuclear magnetic resonance properties of specific endogenous metabolites and native MRI contrast-enhancing biomolecules,label-free molecular and cellular imaging with MRI can be achieved in biomedical research and clinical management of patients with various diseases.This review article outlines the chemical and biological bases of several label-free chemically and molecularly selective MRI and MRS methods that have been applied in imaging biomarker discovery,preclinical investigation,and image-guided clinical management.Examples are provided to demonstrate strategies for using endogenous probes to report the molecular,metabolic,physiological,and functional events and processes in living systems,including patients.Future perspectives on label-free molecular MRI and its challenges as well as potential solutions,including the use of rational design and engineered approaches to develop chemical and biological imaging probes to facilitate or combine with label-free molecular MRI,are discussed.展开更多
基金supported in parts by the grants from NIH(R01CA203388−04,R01AG067736−02)to HM,(R01CA261974,R33HL161756)to GL.CCF is supported,in part,by NIH grant DP2NS127704−01.
文摘Biomedical imaging,especially molecular imaging,has been a driving force in scientific discovery,technological innovation,and precision medicine in the past two decades.While substantial advances and discoveries in chemical biology have been made to develop molecular imaging probes and tracers,translating these exogenous agents to clinical application in precision medicine is a major challenge.Among the clinically accepted imaging modalities,magnetic resonance imaging(MRI)and magnetic resonance spectroscopy(MRS)exemplify the most effective and robust biomedical imaging tools.Both MRI and MRS enable a broad range of chemical,biological diagnosis and characterization of many diseases and image-guided interventions.Using chemical,biological,and nuclear magnetic resonance properties of specific endogenous metabolites and native MRI contrast-enhancing biomolecules,label-free molecular and cellular imaging with MRI can be achieved in biomedical research and clinical management of patients with various diseases.This review article outlines the chemical and biological bases of several label-free chemically and molecularly selective MRI and MRS methods that have been applied in imaging biomarker discovery,preclinical investigation,and image-guided clinical management.Examples are provided to demonstrate strategies for using endogenous probes to report the molecular,metabolic,physiological,and functional events and processes in living systems,including patients.Future perspectives on label-free molecular MRI and its challenges as well as potential solutions,including the use of rational design and engineered approaches to develop chemical and biological imaging probes to facilitate or combine with label-free molecular MRI,are discussed.
